Key facts
- This page summarizes Shefali Agarwal's Form 4 filing for Epizyme, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 16 Aug 2022, 18:57.
Shefali Agarwal - 12 Aug 2022 Form 4 Insider Report for Epizyme, Inc.
- Reporting relationship
- Consultant and Named Executive Officer
- Issuer ticker
- N/A
- Reported as of
- 12 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Aug 2022, 18:57:54 UTC
- Prior SEC filing
- 11 Aug 2022
- Next SEC filing
- 07 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Weidenbruch, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Shefali Agarwal filed Form 4 for Epizyme, Inc. on 16 Aug 2022.
Change
- Previous filing in this sequence was filed on 11 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EPZM
transaction
Common Stock, par value $0.0001
Disposed to Issuer
- Transaction value
- Shares
- -179,247
- Change %
- -63%
- Price
- Shares after
- 107,292
- Date
- 12 Aug 2022
- Ownership
- Direct
- Footnotes
- F1, F2
EPZM
transaction
Common Stock, par value $0.0001
Disposed to Issuer
- Transaction value
- Shares
- -107,292
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Aug 2022
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Shefali Agarwal is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Includes 977 shares of common stock of the Issuer ("Shares") inadvertently omitted from the total Shares directly held by the Reporting Person in the previous Form 4 filed with the Securities and Exchange Commission on February 28, 2022.
Footnote F2
Reflects disposition of Shares in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.
Footnote F3
Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.
SEC remarks
Consultant and Named Executive Officer